Dataset Information

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8⁺ T cells to boost anti-PD-1 therapy.

ABSTRACT: The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8⁺ T cells, especially stem-like CD8⁺ T cells, in tumor tissues. Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R848@M2pep-MPs_AFP) for enhanced anti-PD-1 therapy in HCC. R848@M2pep-MPs_AFP target and reprogram immunosuppressive M2-like tumor-associated macrophages (TAMs) into M1-like phenotype. Meanwhile, R848@M2pep-MPs_AFP-reprogrammed TAMs act as antigen-presenting cells, not only presenting AFP antigen to

SUBMITTER: Zhang X

PROVIDER: S-EPMC10499806 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8⁺ T cells to boost anti-PD-1 therapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8⁺ T cells to boost anti-PD-1 therapy.